康方生物(09926.HK)肺癌藥物美國市場前景受質疑 拖累股價下跌
外電報道,康方生物(09926.HK)股價下跌,因其合作夥伴Summit Therapeutics公布的新數據,令市場對其肺癌藥物ivonescimab在美國的前景產生懷疑。公司早前指,該藥物在後期試驗中呈現出「持續改善的有利」總生存期趨勢,但有分析指出中西方患者數據存在差異。
Summit Therapeutics於2022年獲得該藥物的授權,並一直於全球人群中進行試驗,為在美國獲批鋪路。但今年5月,該藥物未能顯示出統計學意義上的總生存期獲益,令市場失望。
康方生物今早低開1.94%,最低見140元。現報141.6元,跌8.47%,成交3,265.89萬股,涉資46.98億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.